77 related articles for article (PubMed ID: 20592646)
1. Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: a pharmacokinetic study in healthy volunteers.
Hammarberg A; Beck O; Eksborg S; Jayaram-Lindström N; Lindefeldt A; Andersson M; Brundin L; Reid MS; Franck J
Ther Drug Monit; 2010 Aug; 32(4):489-96. PubMed ID: 20592646
[TBL] [Abstract][Full Text] [Related]
2. Analysis of acamprosate in beagle dog plasma by LC-MS-MS.
Rhee YS; Park JH; Park S; Park CW; Ha JM; Jeong KW; Lee DS; Park ES
Arch Pharm Res; 2008 Aug; 31(8):1035-9. PubMed ID: 18787794
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels.
Xu F; Qing Y; Shang B; Liang M; Zou Y; Xu G
Arzneimittelforschung; 2009; 59(12):631-4. PubMed ID: 20108648
[TBL] [Abstract][Full Text] [Related]
4. Urinary ethyl glucuronide and ethyl sulfate testing for recent drinking in alcohol-dependent outpatients treated with acamprosate or placebo.
Dahl H; Hammarberg A; Franck J; Helander A
Alcohol Alcohol; 2011; 46(5):553-7. PubMed ID: 21616946
[TBL] [Abstract][Full Text] [Related]
5. A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration.
Burattini C; McGeehan AJ; Griffin WC; Gass JT; Kinder JR; Janak PH; Olive MF
Addict Biol; 2008 Mar; 13(1):70-9. PubMed ID: 18269381
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.
Mason BJ; Goodman AM; Dixon RM; Hameed MH; Hulot T; Wesnes K; Hunter JA; Boyeson MG
Neuropsychopharmacology; 2002 Oct; 27(4):596-606. PubMed ID: 12377396
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex.
al Qatari M; Bouchenafa O; Littleton J
Alcohol Clin Exp Res; 1998 Jun; 22(4):810-4. PubMed ID: 9660305
[TBL] [Abstract][Full Text] [Related]
8. Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats.
Zornoza T; Cano-Cebrián MJ; Hipólito L; Granero L; Polache A
Biopharm Drug Dispos; 2006 Oct; 27(7):305-11. PubMed ID: 16799924
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain.
Naassila M; Hammoumi S; Legrand E; Durbin P; Daoust M
Alcohol Clin Exp Res; 1998 Jun; 22(4):802-9. PubMed ID: 9660304
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of acamprosate.
Saivin S; Hulot T; Chabac S; Potgieter A; Durbin P; Houin G
Clin Pharmacokinet; 1998 Nov; 35(5):331-45. PubMed ID: 9839087
[TBL] [Abstract][Full Text] [Related]
11. Taurine in plasma and CSF: a study in healthy male volunteers.
Samuelsson M; Dahl ML; Gupta RC; Nordin C
Amino Acids; 2009 Mar; 36(3):529-33. PubMed ID: 18663559
[TBL] [Abstract][Full Text] [Related]
12. Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference.
Kiefer F; Jahn H; Otte C; Nakovics H; Wiedemann K
Neurosci Lett; 2006 Aug; 404(1-2):103-6. PubMed ID: 16782270
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
14. HPLC-APCI-MS/MS method for the determination of catalpol in rat plasma and cerebrospinal fluid: application to an in vivo pharmacokinetic study.
Wang Q; Xing M; Chen W; Zhang J; Qi H; Xu X
J Pharm Biomed Anal; 2012 Nov; 70():337-43. PubMed ID: 22677654
[TBL] [Abstract][Full Text] [Related]
15. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme.
Poldrugo F
Addiction; 1997 Nov; 92(11):1537-46. PubMed ID: 9519495
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
17. Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
Zou JJ; Bian XJ; Ding L; Zhu YB; Fan HW; Xiao DW
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jan; 861(1):151-7. PubMed ID: 18069077
[TBL] [Abstract][Full Text] [Related]
18. A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care.
Kiritzé-Topor P; Huas D; Rosenzweig C; Comte S; Paille F; Lehert P
Alcohol Alcohol; 2004; 39(6):520-7. PubMed ID: 15304381
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
[TBL] [Abstract][Full Text] [Related]
20. Effect of chronic acamprosate treatment on voluntary alcohol intake and beta-endorphin plasma levels in rats selectively bred for high alcohol preference.
Zalewska-Kaszubska J; Górska D; Dyr W; Czarnecka E
Neurosci Lett; 2008 Feb; 431(3):221-5. PubMed ID: 18162308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
